The number of vaccines in development for COVID-19 continues to grow. It may take 12 to 18 months to get a vaccine for COVID-19 approved. Below is information on some of the candidates in development.
mRNA-1273 is a vaccine candidate developed by Moderna and the National Institute of Allergy and Infectious Disease (NIAID) Vaccine Research Center, using prior studies of related coronaviruses, such as severe acute respiratory syndrome and Middle East respiratory syndrome. The clinical trial began recruiting in mid-March and is being conducted at the Kaiser Permanente Washington Health Research Institute in Seattle.
BNT162, a mRNA-based coronavirus vaccine, is being co-developed by Pfizer and BioNTech. It is expected to enter clinical testing in April 2020. BioNTech is also collaborating with Fosun Pharma to develop BNT162 for China.
ChAdOx1 is a chimpanzee adenovirus vaccine vector developed by the Oxford University’s Jennifer Institute. Recruitment is underway for the phase 1 clinical study. The vaccine trial is being run by the Jenner Institute and Oxford Vaccine Group.
Resources
- Milken Institute COVID-19 Treatment and Vaccine Tracker
- RAPS.org COVID-19 Vaccine Tracker
- WHO’s Landscape of COVID-19 candidate vaccines
- Endpoints News COVID-19 Vaccine Tracker
